NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled
NCT02635672 2024-11-15Phase I Dose Escalation Study for VIP152 in Patients With Advanced CancerVincerx Pharma, Inc.Phase 1 Completed110 enrolled
NCT02267603 2023-07-05Pembrolizumab in Treating Patients With Advanced Merkel Cell CancerNational Cancer Institute (NCI)Phase 2 Completed50 enrolled 11 charts 2 FDA
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled